Jazz Pharmaceuticals plc Long-Term Debt

Quick Answer

Jazz Pharmaceuticals plc reported Long-Term Debt of $4.33 billion for fiscal year 2025.

Jazz Pharmaceuticals plc Long-Term Debt — Annual History

Fiscal Year Long-Term Debt YoY Change
2025 $4.33B -28.8%
2024 $6.08B +19.0%
2023 $5.11B -10.3%
2022 $5.69B -5.4%
2021 $6.02B +225.6%
2020 $1.85B +17.5%
2019 $1.57B +0.7%
2018 $1.56B +1.5%
2017 $1.54B -22.7%
2016 $1.99B +73.2%
2015 $1.15B -13.7%
2014 $1.33B +144.9%
2013 $544.40M +27.5%
2012 $427.07M
2011 $0.00

Quarterly Long-Term Debt

Quarter Ending Long-Term Debt YoY QoQ
September 30, 2025 $4.33B -28.8% -0.1%
June 30, 2025 $4.34B -15.0% -18.8%
March 31, 2025 $5.34B +4.5% -12.2%
December 31, 2024 $6.08B +19.0% -0.1%
September 30, 2024 $6.08B +19.0% +19.2%
June 30, 2024 $5.10B -10.3% -0.1%
March 31, 2024 $5.11B -10.3% -0.1%
December 31, 2023 $5.11B -10.3% -0.1%
  • Jazz Pharmaceuticals plc showed a decrease of -28.8% in Long-Term Debt compared to the prior fiscal year.
  • The most recent figure is from Jazz Pharmaceuticals plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment